• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday

    6/26/24 8:12:59 AM ET
    $ACN
    $AMZN
    $ANIP
    $EXAS
    Real Estate
    Real Estate
    Catalog/Specialty Distribution
    Consumer Discretionary
    Get the next $ACN alert in real time by email

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

    • Citigroup raised the price target for NVIDIA Corporation (NASDAQ:NVDA) from $126 to $150. Citigroup analyst Atif Malik maintained a Buy rating. NVIDIA shares gained 6.8% to close at $126.09 on Tuesday. See how other analysts view this stock.
    • Truist Securities raised the price target for Rivian Automotive, Inc. (NASDAQ:RIVN) from $10 to $13. Truist Securities analyst Jordan Levy maintained a Hold rating. Rivian Automotive shares gained 8.6% to close at $11.96 on Tuesday. See how other analysts view this stock.
    • BTIG cut Exact Sciences Corporation (NASDAQ:EXAS) price target from $80 to $70. BTIG analyst Mark Massaro maintained a Buy rating. Exact Sciences shares fell 1.4% to close at $41.37 on Tuesday. See how other analysts view this stock.
    • Morgan Stanley boosted the price target for FedEx Corporation (NYSE:FDX) from $210 to $215. Morgan Stanley analyst Ravi Shanker maintained an Equal-Weight rating. FedEx shares fell 0.1% to close at $256.38 on Tuesday. See how other analysts view this stock.
    • Goldman Sachs cut StoneCo Ltd. (NASDAQ:STNE) price target from $21 to $15. Goldman Sachs analyst Tito Labarta maintained a Buy rating. StoneCo shares gained 1.1% to close at $11.94 on Tuesday. See how other analysts view this stock.
    • B of A Securities raised Amazon.com, Inc. (NASDAQ:AMZN) price target from $210 to $220. B of A Securities analyst Justin Post maintained a Buy rating. Amazon shares gained 0.4% to close at $186.34 on Tuesday. See how other analysts view this stock.
    • HC Wainwright & Co. raised the price target for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) from $87 to $94. HC Wainwright & Co. analyst Oren Livnat maintained a Buy rating. ANI Pharmaceuticals shares gained 2.2% to close at $64.19 on Tuesday. See how other analysts view this stock.
    • Deutsche Bank cut Repligen Corporation (NASDAQ:RGEN) price target from $180 to $155. Deutsche Bank analyst Justin Bowers upgraded the stock from Hold to Buy. Repligen shares fell 0.4% to close at $123.15 on Tuesday. See how other analysts view this stock.
    • BMO Capital raised United States Steel Corporation (NYSE:X) price target from $43 to $45. BMO Capital analyst Katja Jancic upgraded the stock from Market Perform to Outperform. United States Steel shares fell 2.9% to close at $35.21 on Tuesday. See how other analysts view this stock.
    • Morgan Stanley slashed Accenture plc (NYSE:ACN) price target from $382 to $300. Morgan Stanley analyst James Faucette downgraded the stock from Overweight to Equal-Weight. Accenture shares slipped 0.01% to close at $307.17 on Tuesday. See how other analysts view this stock.

    Check This Out: FedEx, Micron And 3 Stocks To Watch Heading Into Wednesday

    Get the next $ACN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACN
    $AMZN
    $ANIP
    $EXAS

    CompanyDatePrice TargetRatingAnalyst
    Rivian Automotive Inc.
    $RIVN
    2/13/2026$23.00Hold → Buy
    Deutsche Bank
    Rivian Automotive Inc.
    $RIVN
    2/13/2026$16.00Sell → Neutral
    UBS
    FedEx Corporation
    $FDX
    2/13/2026$313.00 → $383.00Buy
    TD Cowen
    StoneCo Ltd.
    $STNE
    2/9/2026$22.00Buy
    BTIG Research
    Amazon.com Inc.
    $AMZN
    2/6/2026$300.00 → $280.00Buy
    Monness Crespi & Hardt
    Amazon.com Inc.
    $AMZN
    2/6/2026$175.00Buy → Neutral
    DA Davidson
    FedEx Corporation
    $FDX
    2/3/2026$380.00Equal Weight → Overweight
    Wells Fargo
    FedEx Corporation
    $FDX
    2/3/2026$427.00Mkt Perform → Outperform
    Bernstein
    More analyst ratings

    $ACN
    $AMZN
    $ANIP
    $EXAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Worldwide Amazon Stores Herrington Douglas J sold $208,000 worth of shares (1,000 units at $208.00), decreasing direct ownership by 0.20% to 504,934 units (SEC Form 4)

    4 - AMAZON COM INC (0001018724) (Issuer)

    2/13/26 5:08:40 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    SVP & CFO Carey Stephen P. covered exercise/tax liability with 5,503 shares, decreasing direct ownership by 3% to 175,360 units (SEC Form 4)

    4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

    2/13/26 4:13:54 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SR. VP, GENERAL COUNSEL & SEC. Cook Meredith covered exercise/tax liability with 3,011 shares, decreasing direct ownership by 4% to 71,363 units (SEC Form 4)

    4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

    2/13/26 4:13:17 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACN
    $AMZN
    $ANIP
    $EXAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Madaus Martin D bought $201,830 worth of shares (1,800 units at $112.13) (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    8/12/25 12:47:07 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Pax Margaret bought $37,672 worth of shares (250 units at $150.69), increasing direct ownership by 32% to 1,043 units (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    3/18/25 3:58:05 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP CHIEF FINANCIAL OFF Dietrich John W bought $273,980 worth of shares (1,000 units at $273.98), increasing direct ownership by 12% to 9,067 units (SEC Form 4)

    4 - FEDEX CORP (0001048911) (Issuer)

    1/8/25 7:43:16 PM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    $ACN
    $AMZN
    $ANIP
    $EXAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rivian Automotive upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Rivian Automotive from Hold to Buy and set a new price target of $23.00

    2/13/26 10:14:02 AM ET
    $RIVN
    Auto Manufacturing
    Industrials

    Rivian Automotive upgraded by UBS with a new price target

    UBS upgraded Rivian Automotive from Sell to Neutral and set a new price target of $16.00

    2/13/26 8:26:09 AM ET
    $RIVN
    Auto Manufacturing
    Industrials

    TD Cowen reiterated coverage on FedEx with a new price target

    TD Cowen reiterated coverage of FedEx with a rating of Buy and set a new price target of $383.00 from $313.00 previously

    2/13/26 8:02:23 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    $ACN
    $AMZN
    $ANIP
    $EXAS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Exact Sciences Corporation

    SCHEDULE 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

    2/13/26 5:32:39 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Exact Sciences Corporation

    10-K - EXACT SCIENCES CORP (0001124140) (Filer)

    2/13/26 4:09:33 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Exact Sciences Corporation

    8-K - EXACT SCIENCES CORP (0001124140) (Filer)

    2/13/26 4:06:18 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $ACN
    $AMZN
    $ANIP
    $EXAS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results

    Fourth quarter and 2025 highlights Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Precision Oncology revenue of $183 million Total 2025 revenue of $3.25 billion, an increase of 18% on a reported and core revenue basis, with Screening revenue of $2.53 billion and Precision Oncology revenue of $717 million Operating cash flow was $491 million and free cash flow was $357 million for the full-year 2025, an improvement of 133% and 379%, respectively Net loss was $208 million and adjusted EBITDA was $400 million for the full-year 2025, an improvement of $821 million and $77 million, resp

    2/13/26 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    FedEx Joins Hedera Council to Support the Future of Digital Global Supply Chains

    Contributing the company's extensive operational expertise and perspective to support cooperative approaches to distributed infrastructure. MEMPHIS, Tenn., Feb. 13, 2026 /PRNewswire/ -- FedEx Corp. (NYSE:FDX) today announced joining Hedera Council, a governing body made up of leading global organizations dedicated to fostering trust, security, and innovation on the Hedera network. FedEx joins the Council to help advance trusted digital infrastructure that can support the evolving lifecycle of global shipments and make supply chains smarter for everyone. FedEx's participation i

    2/13/26 11:00:00 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    FedEx Corp. Board Declares Quarterly Dividend

    The Board of Directors of FedEx Corp. (NYSE:FDX) today declared a quarterly cash dividend of $1.45 per share on FedEx Corp. common stock, in line with the company's continued focus on delivering stockholder value. The dividend is payable April 1, 2026, to stockholders of record at the close of business on March 9, 2026. FedEx Corp. (NYSE:FDX) provides customers and businesses worldwide with a broad portfolio of transportation, e-commerce and business services. With annual revenue of $90 billion, the company offers integrated business solutions utilizing its flexible, efficient, and intelligent global network. Consistently ranked among the world's most admired and trusted employers, FedEx

    2/13/26 9:01:00 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    $ACN
    $AMZN
    $ANIP
    $EXAS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 11, 2025 - FDA Roundup: March 11, 2025

    For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

    3/13/25 3:14:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    November 14, 2023 - FDA Roundup: November 14, 2023

    For Immediate Release: November 14, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA updated the advisory for the Investigation of Elevated Lead Levels in Cinnamon Applesauce Pouches to include an expanded recall from WanaBana LLC to include Weis and Schnucks-brand cinnamon applesauce pouches. As of November 13, 2023, there

    11/14/23 3:26:18 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN

    Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling

    3/8/21 5:11:24 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACN
    $AMZN
    $ANIP
    $EXAS
    Leadership Updates

    Live Leadership Updates

    View All

    Accenture Appoints Rachel Frey Chief Communications Officer

    Accenture (NYSE:ACN) today announced the appointment of Rachel Frey as chief communications officer, a newly created role. Effective immediately, Frey reports to Accenture Chair and CEO Julie Sweet and joins Accenture's Global Management Committee. Frey brings more than two decades of experience in communications. In her most recent role as Accenture's global head of Corporate Communications, she strengthened the company's relationships with external audiences; developed and elevated an enhanced earned communications strategy that has strategically positioned Accenture and its leaders at the forefront of AI reinvention across every major sector and region around the world; and leveraged d

    2/11/26 10:43:00 AM ET
    $ACN
    Real Estate

    Circana Appoints Highly Regarded Business Leaders to Board of Directors

    Chicago, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Circana LLC, a leading global provider of data, insights, and advisory services, today announced the appointment of three new members to its Board of Directors: Brian Cornell, Executive Chair of Target Corp.; Lauren Cooks Levitan, Co-Founder and Co-CEO of ROOT and Lead Independent Director at e.l.f. Beauty, Inc.; and Rohit Prasad, former Senior Vice President and Head Scientist of Artificial General Intelligence at Amazon.com, Inc. "These appointments strengthen the Board's ability to guide Circana's strategy and accelerate the value we deliver to our global clients," said Stuart Aitken, President and CEO of Circana. "We are focused on advancing

    2/11/26 8:00:00 AM ET
    $AMZN
    $TGT
    Catalog/Specialty Distribution
    Consumer Discretionary
    Department/Specialty Retail Stores

    FedEx Appoints Scott Ray as Chief Operating Officer for U.S. and Canada Surface Operations

    FedEx Corp. (NYSE:FDX) today announced the appointment of Scott Ray as chief operating officer for U.S. and Canada Surface Operations, effective June 1. He will begin transitioning into the role as COO-elect on Feb. 1. Reporting to FedEx President and CEO Raj Subramaniam, Ray will be the newest member of the FedEx Executive Committee, succeeding John Smith, who will transition to CEO of FedEx Freight as of June 1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126094399/en/FedEx appoints Scott Ray as chief operating officer of Surface Operations in U.S. and Canada Ray will be responsible for leading all aspects of Surface Ope

    1/27/26 8:31:00 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    $ACN
    $AMZN
    $ANIP
    $EXAS
    Financials

    Live finance-specific insights

    View All

    Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results

    Fourth quarter and 2025 highlights Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Precision Oncology revenue of $183 million Total 2025 revenue of $3.25 billion, an increase of 18% on a reported and core revenue basis, with Screening revenue of $2.53 billion and Precision Oncology revenue of $717 million Operating cash flow was $491 million and free cash flow was $357 million for the full-year 2025, an improvement of 133% and 379%, respectively Net loss was $208 million and adjusted EBITDA was $400 million for the full-year 2025, an improvement of $821 million and $77 million, resp

    2/13/26 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    FedEx Corp. Board Declares Quarterly Dividend

    The Board of Directors of FedEx Corp. (NYSE:FDX) today declared a quarterly cash dividend of $1.45 per share on FedEx Corp. common stock, in line with the company's continued focus on delivering stockholder value. The dividend is payable April 1, 2026, to stockholders of record at the close of business on March 9, 2026. FedEx Corp. (NYSE:FDX) provides customers and businesses worldwide with a broad portfolio of transportation, e-commerce and business services. With annual revenue of $90 billion, the company offers integrated business solutions utilizing its flexible, efficient, and intelligent global network. Consistently ranked among the world's most admired and trusted employers, FedEx

    2/13/26 9:01:00 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET

    PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to discuss the results as follows: DateFriday, February 27, 2026Time8:00 a.m. ETToll free (U.S.)800-274-8461Conference ID5230834Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section The live and arc

    2/13/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACN
    $AMZN
    $ANIP
    $EXAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by United States Steel Corporation

    SC 13G - UNITED STATES STEEL CORP (0001163302) (Subject)

    11/14/24 4:05:43 PM ET
    $X
    Steel/Iron Ore
    Industrials

    Amendment: SEC Form SC 13G/A filed by Repligen Corporation

    SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

    11/14/24 1:22:37 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by ANI Pharmaceuticals Inc.

    SC 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)

    11/13/24 4:30:24 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care